Search


Current filters:




Start a new search
Add filters:

Use filters to refine the search results.


Results 1-9 of 9 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2015Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non–small-cell lung cancerRamalingam, S.S.; Shtivelband, M.; Soo, R.A.; Barrios, C.H.; Makhson, A.; Segalla, J.G.; Pittman, K.B.; Kolman, P.; Pereira, J.R.; Srkalovic, G.; Belani, C.P.; Axelrod, R.; Owonikoko, T.K.; Qin, Q.; Qian, J.; McKeegan, E.M.; Devanarayan, V.; McKee, M.D.; Ricker, J.L.; Carlson, D.M.; et al.
2013Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomesCho, Y.; Badve, S.; Hawley, C.; McDonald, S.; Brown, F.; Boudville, N.; Bannister, K.; Clayton, P.; Johnson, D.
2015A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinomaPal, S.; Azad, A.; Bhatia, S.; Drabkin, H.; Costello, B.; Sarantopoulos, J.; Kanesvaran, R.; Lauer, R.; Starodub, A.; Hauke, R.; Sweeney, C.; Hahn, N.; Sonpavde, G.; Richey, S.; Breen, T.; Kremmidiotis, G.; Leske, A.; Doolin, E.; Bibby, D.; Simpson, J.; et al.
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Vickers, M.; Karapetis, C.; Tu, D.; O'Callaghan, C.; Price, T.; Tebbutt, N.; van Hazel, G.; Shapiro, J.; Pavlakis, N.; Gibbs, P.; Blondal, J.; Lee, U.; Meharchand, J.; Burkes, R.; Rubin, S.; Simes, J.; Zalcberg, J.; Moore, M.; Zhu, L.; Jonker, D.
2012Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trialBurmeister, B.; Henderson, M.; Ainslie, J.; Fisher, R.; Di Iulio, J.; Smithers, B.; Hong, A.; Shannon, K.; Scolyer, R.; Carruthers, S.; Coventry, B.; Babington, S.; Duprat, J.; Hoekstra, H.; Thompson, J.
2010Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
2010Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerPeeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.; Rong, A.; Gansert, J.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
2015Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant Therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trialSchmoll, H.; Tabernero, J.; Maroun, J.; de Braud, F.; Price, T.; Van Cutsem, E.; Hill, M.; Hoersch, S.; Rittweger, K.; Haller, D.